Tags : Reduce

Merck and Bayer Receive the US FDA’s Priority Review for

Shots: The NDA is based on P-III VICTORIA study assessing vericiguat (qd, (titrated up to 10mg) vs PBO when given in combination with available HF therapies in ~5,050 patients with worsening CHF, reduced left VEF of <45% within 12mos. prior to randomization following a decompensation event The 1EPs is the composite of time to the […]Read More

Baysient to Release iDose Software Technology Platform 1.0 to Reduce

The 12-month clinical validation study (NCT02453776) data demonstrated the reduction “switching” from lower cost infliximab to more expensive biologics by 66%. Also, similar studies are ongoing in 9 countries on 3 continents The results were already presented at ECCO, Copenhagen, Mar 2019 and DDW, San Diego, May 2019 and the Baysient pipeline includes CDS for […]Read More

Astellas Reports Results of Mirabegron in P-IV PLUS Study to

Shots: The P-IV PLUS study involves assessing of Mirabegron(25mg,50mg) vs PBO in 715 men patients with overactive bladder (OAB) symptoms receiving tamsulosin for lower urinary tract symptoms (LUTS) due to underlying benign prostatic hyperplasia (BPH) aged ≥40 yrs. The P-IV PLUS study results: @12wks. reduction in no. of micturition/day, increment in mean volume voided (MVV)/micturition, […]Read More